Abstract
Glioma represents the lethal neoplasm of the brain with dismal progression in its most aggressive form, that is, glioblastoma. Hypoxia is well appreciated to have a role in cellular migration and proliferation of a range of malignancies; however, its multifaceted impact on tumors of glial origin is not clear. The aim of present chapter is to present the integrated view of hypoxia involvement in the biology of gliomas. Hypoxia impacts the biology of glioma mainly through the transcriptional factors HIF1 alpha and exists in spatiotemporal heterogeneity in its expression in the tumor. The hypoxic microenvironment impacts the pathology of glioma on account of several mechanisms such as by altering the metabolic switch from oxidative to glycolytic metabolism, promoting the expression of tumor, promoting signaling in the form of VEGF, PI3k, and MAP kinase cascade. In addition, hypoxia is notorious to induce the refractiveness to the existing therapies such as radiation and temozolomide-mediated chemotherapy. Targeting hypoxia mediators in combination with the present therapeutic regime could potentially sensitize glioma cells to induce cell death and prevent the inevitable recurrence.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahmed EM, Bandopadhyay G, Coyle B, Grabowska A (2018) A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells. Cell Oncol (Dordr) 41:319–328. https://doi.org/10.1007/s13402-018-0374-8
Bae YS, Kang SW, Seo MS, Baines IC, Tekle E, Chock PB, Rhee SG (1997) Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J Biol Chem 272:217–221
Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11:889–896. https://doi.org/10.1038/ni.1937
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462–477. https://doi.org/10.1016/j.cell.2013.09.034
Brucker DP, Maurer GD, Harter PN, Rieger J, Steinbach JP (2016) FOXO3a orchestrates glioma cell responses to starvation conditions and promotes hypoxia-induced cell death. Int J Oncol 49:2399–2410. https://doi.org/10.3892/ijo.2016.3760
Buhr ED, Takahashi JS (2013) Molecular components of the mammalian circadian clock. Handb Exp Pharmacol. https://doi.org/10.1007/978-3-642-25950-0_1,3-27, https://doi.org/10.1007/978-3-642-25950-0_1
Candolfi M, Curtin JF, Yagiz K, Assi H, Wibowo MK, Alzadeh GE, Foulad D, Muhammad AK, Salehi S, Keech N et al (2011) B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. Neoplasia 13:947–960. https://doi.org/10.1593/neo.11024
Cemerski S, Cantagrel A, Van Meerwijk JP, Romagnoli P (2002) Reactive oxygen species differentially affect T cell receptor-signaling pathways. J Biol Chem 277:19585–19593. https://doi.org/10.1074/jbc.M111451200
Chance B, Sies H, Boveris A (1979) Hydroperoxide metabolism in mammalian organs. Physiol Rev 59:527–605. https://doi.org/10.1152/physrev.1979.59.3.527
Chang WH, Lai AG (2019) Timing gone awry: distinct tumour suppressive and oncogenic roles of the circadian clock and crosstalk with hypoxia signalling in diverse malignancies. J Transl Med 17:132. https://doi.org/10.1186/s12967-019-1880-9
Chen Z, Liu P, Li C, Luo Y, Chen I, Liang W, Chen X, Feng Y, **a H, Wang F (2013) Deregulated expression of the clock genes in gliomas. Technol Cancer Res Treat 12:91–97. https://doi.org/10.7785/tcrt.2012.500250
Chiacchiera F, Simone C (2010) The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle 9:1091–1096. https://doi.org/10.4161/cc.9.6.11035
Cohen DJ, Norris LP, Montemayor IE, O’Rourke RA, Zabalgoitia M (1992) Systolic anterior motion of the chordal apparatus after mitral ring insertion. Am Heart J 124:666–670. https://doi.org/10.1016/0002-8703(92)90275-z
Crane CA, Ahn BJ, Han SJ, Parsa AT (2012) Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro-Oncology 14:584–595. https://doi.org/10.1093/neuonc/nos014
Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, Chopra S, Perales-Puchalt A, Song M, Zhang S, Bettigole SE, Gupta D, Holcomb K et al (2015) ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161:1527–1538. https://doi.org/10.1016/j.cell.2015.05.025
Dalerba P, Cho RW, Clarke MF (2007) Cancer stem cells: models and concepts. Annu Rev Med 58:267–284. https://doi.org/10.1146/annurev.med.58.062105.204854
Dermit M, Casado P, Rajeeve V, Wilkes EH, Foxler DE, Campbell H, Critchlow S, Sharp TV, Gribben JG, Unwin R et al (2017) Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition. Oncogene 36:2762–2774. https://doi.org/10.1038/onc.2016.435
Deshpande RP, Sharma S, Watabe K (2020) The confounders of cancer immunotherapy: roles of lifestyle, metabolic disorders and sociological factors. Cancers (Basel) 12. https://doi.org/10.3390/cancers12102983
Dewhirst MW, Cao Y, Moeller B (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8:425–437. https://doi.org/10.1038/nrc2397
Ebert LM, Tan BS, Browning J, Svobodova S, Russell SE, Kirkpatrick N, Gedye C, Moss D, Ng SP, MacGregor D et al (2008) The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res 68:3001–3009. https://doi.org/10.1158/0008-5472.Can-07-5664
Eissa AM, Saad MA, Abdel Ghaffar AK, el-Sharkaway IM, Kamal KA (1989) Transmission of lymphocyte responsiveness to schistosomal antigens by breast feeding. Trop Geogr Med 41:208–212
Giese A, Bjerkvig R, Berens ME, Westphal M (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21:1624–1636. https://doi.org/10.1200/jco.2003.05.063
Gorrini C, Harris IS, Mak TW (2013) Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12:931–947. https://doi.org/10.1038/nrd4002
Grek CL, Sheng Z, Naus CC, Sin WC, Gourdie RG, Ghatnekar GG (2018) Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics. Curr Opin Pharmacol 41:79–88. https://doi.org/10.1016/j.coph.2018.05.002
Griendling KK, Sorescu D, Lassègue B, Ushio-Fukai M (2000) Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 20:2175–2183. https://doi.org/10.1161/01.atv.20.10.2175
Hatterer E, Davoust N, Didier-Bazes M, Vuaillat C, Malcus C, Belin MF, Nataf S (2006) How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes. Blood 107:806–812. https://doi.org/10.1182/blood-2005-01-0154
Jensen RL, Ragel BT, Whang K, Gillespie D (2006) Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J Neuro-Oncol 78:233–247. https://doi.org/10.1007/s11060-005-9103-z
Johannessen TC, Hasan-Olive MM, Zhu H, Denisova O, Grudic A, Latif MA, Saed H, Varughese JK, Røsland GV, Yang N et al (2019) Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide. Int J Cancer 144:1735–1745. https://doi.org/10.1002/ijc.31912
Kaminski MM, Sauer SW, Klemke CD, Süss D, Okun JG, Krammer PH, Gülow K (2010) Mitochondrial reactive oxygen species control T cell activation by regulating IL-2 and IL-4 expression: mechanism of ciprofloxacin-mediated immunosuppression. J Immunol 184:4827–4841. https://doi.org/10.4049/jimmunol.0901662
Kitange GJ, Mladek AC, Schroeder MA, Pokorny JC, Carlson BL, Zhang Y, Nair AA, Lee JH, Yan H, Decker PA et al (2016) Retinoblastoma binding protein 4 modulates temozolomide sensitivity in glioblastoma by regulating DNA repair proteins. Cell Rep 14:2587–2598. https://doi.org/10.1016/j.celrep.2016.02.045
Knapp LT, Klann E (2002) Role of reactive oxygen species in hippocampal long-term potentiation: contributory or inhibitory? J Neurosci Res 70:1–7. https://doi.org/10.1002/jnr.10371
Kwon J, Lee SR, Yang KS, Ahn Y, Kim YJ, Stadtman ER, Rhee SG (2004) Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci U S A 101:16419–16424. https://doi.org/10.1073/pnas.0407396101
Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149:274–293. https://doi.org/10.1016/j.cell.2012.03.017
Leder A, Kuo A, Shen MM, Leder P (1992) In situ hybridization reveals co-expression of embryonic and adult alpha globin genes in the earliest murine erythrocyte progenitors. Development 116:1041–1049
Lo Dico A, Martelli C, Diceglie C, Lucignani G, Ottobrini L (2018) Hypoxia-inducible factor-1α activity as a switch for glioblastoma responsiveness to temozolomide. Front Oncol 8:249. https://doi.org/10.3389/fonc.2018.00249
Lo Dico A, Salvatore D, Martelli C, Ronchi D, Diceglie C, Lucignani G, Ottobrini L (2019) Intracellular redox-balance involvement in Temozolomide resistance-related molecular mechanisms in glioblastoma. Cell 8. https://doi.org/10.3390/cells8111315
Locasale JW, Cantley LC (2011) Metabolic flux and the regulation of mammalian cell growth. Cell Metab 14:443–451. https://doi.org/10.1016/j.cmet.2011.07.014
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109. https://doi.org/10.1007/s00401-007-0243-4
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1
Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS et al (2015) Structural and functional features of central nervous system lymphatic vessels. Nature 523:337–341. https://doi.org/10.1038/nature14432
Luo S, Lei K, **ang D, Ye K (2018) NQO1 is regulated by PTEN in glioblastoma, mediating cell proliferation and oxidative stress. Oxidative Med Cell Longev 2018:9146528. https://doi.org/10.1155/2018/9146528
Madden MH, Anic GM, Thompson RC, Nabors LB, Olson JJ, Browning JE, Monteiro AN, Egan KM (2014) Circadian pathway genes in relation to glioma risk and outcome. Cancer Causes Control 25:25–32. https://doi.org/10.1007/s10552-013-0305-y
Maj T, Wang W, Crespo J, Zhang H, Wang W, Wei S, Zhao L, Vatan L, Shao I, Szeliga W et al (2017) Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol 18:1332–1341. https://doi.org/10.1038/ni.3868
Matsushita M, Freigang S, Schneider C, Conrad M, Bornkamm GW, Kopf M (2015) T cell lipid peroxidation induces ferroptosis and prevents immunity to infection. J Exp Med 212:555–568. https://doi.org/10.1084/jem.20140857
Mecca C, Giambanco I, Donato R, Arcuri C (2018) Targeting mTOR in glioblastoma: rationale and preclinical/clinical evidence. Dis Markers 2018:9230479. https://doi.org/10.1155/2018/9230479
Méndez-Lucas A, Hyroššová P, Novellasdemunt L, Viñals F, Perales JC (2014) Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) is a pro-survival, endoplasmic reticulum (ER) stress response gene involved in tumor cell adaptation to nutrient availability. J Biol Chem 289:22090–22102. https://doi.org/10.1074/jbc.M114.566927
Pero RW, Roush GC, Markowitz MM, Miller DG (1990) Oxidative stress, DNA repair, and cancer susceptibility. Cancer Detect Prev 14:555–561
Razavi SM, Lee KE, ** BE, Aujla PS, Gholamin S, Li G (2016) Immune evasion strategies of glioblastoma. Front Surg 3:11. https://doi.org/10.3389/fsurg.2016.00011
Reardon DA, Freeman G, Wu C, Chiocca EA, Wucherpfennig KW, Wen PY, Fritsch EF, Curry WT Jr, Sampson JH, Dranoff G (2014) Immunotherapy advances for glioblastoma. Neuro-Oncology 16:1441–1458. https://doi.org/10.1093/neuonc/nou212
Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715–725. https://doi.org/10.1038/nri2155
Salazar-Ramiro A, Ramírez-Ortega D, Pérez de la Cruz V, Hérnandez-Pedro NY, González-Esquivel DF, Sotelo J, Pineda B (2016) Role of redox status in development of glioblastoma. Front Immunol 7:156. https://doi.org/10.3389/fimmu.2016.00156
Sampson JH, Maus MV, June CH (2017) Immunotherapy for brain tumors. J Clin Oncol 35:2450–2456. https://doi.org/10.1200/jco.2017.72.8089
Sancar G, Brunner M (2014) Circadian clocks and energy metabolism. Cell Mol Life Sci 71:2667–2680. https://doi.org/10.1007/s00018-014-1574-7
Saso L, Firuzi O (2014) Pharmacological applications of antioxidants: lights and shadows. Curr Drug Targets 15:1177–1199. https://doi.org/10.2174/1389450115666141024113925
Schartner JM, Hagar AR, Van Handel M, Zhang L, Nadkarni N, Badie B (2005) Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia 51:279–285. https://doi.org/10.1002/glia.20201
Schibler U, Sassone-Corsi P (2002) A web of circadian pacemakers. Cell 111:919–922. https://doi.org/10.1016/s0092-8674(02)01225-4
Seidel S, Garvalov BK, Wirta V, von Stechow L, Schänzer A, Meletis K, Wolter M, Sommerlad D, Henze AT, Nistér M et al (2010) A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 133:983–995. https://doi.org/10.1093/brain/awq042
Stevens RG, Blask DE, Brainard GC, Hansen J, Lockley SW, Provencio I, Rea MS, Reinlib L (2007) Meeting report: the role of environmental lighting and circadian disruption in cancer and other diseases. Environ Health Perspect 115:1357–1362. https://doi.org/10.1289/ehp.10200
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330
Taïb B, Aboussalah AM, Moniruzzaman M, Chen S, Haughey NJ, Kim SF, Ahima RS (2019) Lipid accumulation and oxidation in glioblastoma multiforme. Sci Rep 9:19593. https://doi.org/10.1038/s41598-019-55985-z
Tan M, Li S, Swaroop M, Guan K, Oberley LW, Sun Y (1999) Transcriptional activation of the human glutathione peroxidase promoter by p53. J Biol Chem 274:12061–12066. https://doi.org/10.1074/jbc.274.17.12061
Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, Zhang Z, Zhang H, Teng Q, Nicholson AC, Giannakakou P et al (2005) Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 65:605–612
Touat M, Idbaih A, Sanson M, Ligon KL (2017) Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann Oncol 28:1457–1472. https://doi.org/10.1093/annonc/mdx106
Uribe D, Torres Á, Rocha JD, Niechi I, Oyarzún C, Sobrevia L, San Martín R, Quezada C (2017) Multidrug resistance in glioblastoma stem-like cells: role of the hypoxic microenvironment and adenosine signaling. Mol Asp Med 55:140–151. https://doi.org/10.1016/j.mam.2017.01.009
Vazquez F, Lim JH, Chim H, Bhalla K, Girnun G, Pierce K, Clish CB, Granter SR, Widlund HR, Spiegelman BM et al (2013) PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 23:287–301. https://doi.org/10.1016/j.ccr.2012.11.020
Wang X, Michaelis EK (2010) Selective neuronal vulnerability to oxidative stress in the brain. Front Aging Neurosci 2:12. https://doi.org/10.3389/fnagi.2010.00012
Wesseling P, Capper DWHO (2016) Classification of gliomas. Neuropathol Appl Neurobiol 2018(44):139–150. https://doi.org/10.1111/nan.12432
**a HC, Niu ZF, Ma H, Cao SZ, Hao SC, Liu ZT, Wang F (2010) Deregulated expression of the Per1 and Per2 in human gliomas. Can J Neurol Sci 37:365–370. https://doi.org/10.1017/s031716710001026x
Yilmaz N, Dulger H, Kiymaz N, Yilmaz C, Bayram I, Ragip B, Oğer M (2006) Lipid peroxidation in patients with brain tumor. Int J Neurosci 116:937–943. https://doi.org/10.1080/00207450600553141
Yu C, Yang SL, Fang X, Jiang JX, Sun CY, Huang T (2015) Hypoxia disrupts the expression levels of circadian rhythm genes in hepatocellular carcinoma. Mol Med Rep 11:4002–4008. https://doi.org/10.3892/mmr.2015.3199
Zhang Y, Dube C, Gibert M Jr, Cruickshanks N, Wang B, Coughlan M, Yang Y, Setiady I, Deveau C, Saoud K et al (2018) The p53 pathway in glioblastoma. Cancers (Basel) 10. https://doi.org/10.3390/cancers10090297
Zhao Y, Hu X, Liu Y, Dong S, Wen Z, He W, Zhang S, Huang Q, Shi M (2017) ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway. Mol Cancer 16:79. https://doi.org/10.1186/s12943-017-0648-1
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2022 Springer Nature Singapore Pte Ltd.
About this entry
Cite this entry
Deshpande, R.P., Babu, P.P. (2022). Reactive Oxygen Species in Glioma. In: Chakraborti, S. (eds) Handbook of Oxidative Stress in Cancer: Therapeutic Aspects. Springer, Singapore. https://doi.org/10.1007/978-981-16-5422-0_145
Download citation
DOI: https://doi.org/10.1007/978-981-16-5422-0_145
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-5421-3
Online ISBN: 978-981-16-5422-0
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences